Abstracts tagged "end-stage renal disease"

Abstract Number: 0769 • ACR Convergence 2021
Renal Outcomes in 1528 Childhood-onset Systemic Lupus Erythematosus Patients: A Brazilian Multicenter Study
Ana Paula Sakamoto¹, Clovis Silva², Aline Islabão³, Glaucia Novak², Beatriz Molinari², Rosa Pereira⁴, Claudia Saad-Magalhães⁵, Gleice Clemente⁶, Daniela Petry Pioto⁷, Nadia Aikawa⁴, Ana Pita², Vitor Trindade², Simone Appenzeller⁸, Luciana Carvalho⁹, Carlos Rabelo-Junior¹⁰, Adriana Fonseca¹¹, Flavio Sztajnbok¹², Maria Santos¹³, Blanca Elena Rios Gomes Bica¹⁴, Evaldo Sena¹⁵, Ana Moraes¹⁶, Melissa Fraga⁶, Teresa Robazzi¹⁷, Paulo Spelling¹⁸, Iloite Scheibel¹⁹, Andre Cavalcanti²⁰, Erica Matos²¹, Luciano Guimarães²², Flavia Santos²³, Licia Maria Henrique Mota²⁴, Eloisa Bonfá⁴ and Maria Terreri²⁵, ¹Federal University of So Paulo (UNIFESP), São Paulo, Brazil, ²Pediatric Rheumatology Unit, Children’s Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Hospital da Criança de Brasília Jose Alencar, Brasilia, DF, Brazil, ⁴Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Division, São Paulo State University (UNESP) – Faculdade de Medicina de Botucatu, Botucatu, Botucatu, Brazil, ⁶Universidade Federal de São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, SP, Brazil, ⁸Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ⁹Pediatric Rheumatology Unit, Ribeirão Preto Medical School – University of São Paulo, Ribeirão Preto, SP, Brazil, ¹⁰Pediatric Rheumatology Unit, Hospital Geral de Fortaleza, Fortaleza, CE, Brazil, ¹¹Pediatric Rheumatology Unit, Rio de Janeiro Federal University (IPPMG-UFRJ), Rio de Janeiro, RJ, Brazil, ¹²UFRJ/UERJ, Rio de Janeiro, Brazil, ¹³Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil, ¹⁴Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵Pediatric Rheumatology Unit, Lauro Vanderley University Hospital, João Pessoa, PB, Brazil, ¹⁶Pediatric Rheumatology Unit, Federal University of Pará, Belém, PA, Brazil, ¹⁷Pediatric Rheumatology Unit, Federal University of Bahia, Salvador, BA, Brazil, ¹⁸Pediatric Rheumatology Unit, Hospital Evangélico de Curitiba, Curitiba, PR, Brazil, ¹⁹Pediatric Rheumatology Unit, Hospital Criança Conceição, Porto Alegre, RS, Brazil, ²⁰Pediatric Rheumatology Unit, Federal University of Pernambuco, Recife, PE, Brazil, ²¹Pediatric Rheumatology Unit, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil, ²²Pediatric Rheumatology Unit, University of Brasília, Brasilia, DF, Brazil, ²³Pediatric Rheumatology Unit, Federal University of Minas Gerais, Belo Horizonte, Belo Horizonte, MG, Brazil, ²⁴Universidade de Brasília, Brasilia, Brazil, ²⁵UNIFESP, São Paulo, Brazil
Background/Purpose: Lupus nephritis is a frequent manifestation in childhood-onset systemic lupus erythematosus (cSLE) and has a great potential for chronic kidney disease (CKD), requiring dialysis…
Abstract Number: 0954 • ACR Convergence 2021
The Association of Rituximab- vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis
Zachary Wallace¹, Xiaoqing Fu², Claire Cook³, Yuqing Zhang⁴, John Stone⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital, Lexington, MA
Background/Purpose: The RAVE trial established the non-inferiority of rituximab (RTX) vs cyclophosphamide (CYC) for remission induction of ANCA-Associated Vasculitis (AAV). Patients in RAVE were followed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].